《高盛認股證牛熊證》醫藥板塊急挫 留意貼價復星購24829、中期購26102,藥明價外購27921
正股表現:美國默克藥廠上週表示,與另一企業聯合研發的新冠病毒口服藥物Molnupiravir,有效將確診者入院或死亡風險減低一半。並表示將爲該藥物申請緊急使用授權。消息拖累醫藥板塊受壓,多隻醫藥股今早急挫。
藥明生物(2269)由上週一起連升4日,累計升逾7%。今早低開約1.7%後急挫並失守120元水平,最低見116.3元,爲過去兩週低位。現報117.2元,跌約7.4%。
此外,復星醫藥(2196)由中秋節假期後開始連跌,當中上週四跌約1%,今早繼續下跌。早上低開約4.5%後急挫,最低見31.6元,爲半年低位。現報32.25元,跌約19.5%。
資金流向:觀察個股輪證資金流向,可見上週四流入藥明牛證的資金集中在114元以上收回價的貼牛。
復星方面,可見認購證持續獲資金部署,過去5個交易日共錄得約220萬元資金流入。
產品選擇:投資者如看好藥明生物,認購證方面的貼價選擇可留意屬短期、高槓杆的藥明購24829。中期選擇可留意低街貨藥明購26102。牛證方面的近牛選擇可留意藥明牛67083,與現價有約7元收回距離。遠牛選擇可留意藥明牛66248,與現價有約22元收回距離。
藥明購24829,行使價130.88元,2021年11月25日到期,實際槓桿7.1倍,貼價、短期、高槓杆
藥明購26102,行使價138元,2022年01月21日到期,實際槓桿5.2倍,中期、低街貨
藥明牛67083,收回價110元,行使價108.5元,換股比率100,槓桿比率13.1倍,相近收回價近牛中槓桿最高
藥明牛66248,收回價95元,行使價93.5元,換股比率100,槓桿比率4.9倍,相近收回價遠牛中街貨較
投資者如看好復星醫藥,可留意屬價外、中期的復醫購27921。
復醫購27921,行使價51.93元,2022年05月24日到期,實際槓桿5.2倍,價外、中期
注: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.